Back to Search
MARIO EISENBERGER, M.D.
M.D.
Medical Oncology Physician
NPI: 1699722850Individual
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
D28768(MD)
Research & Publications (20)
The role of cytotoxic chemotherapy in prostate cancer. A critical reevaluation 20 years later.
PMID 16922258·Oncology (Williston Park)·2006
6-review
Phase I and clinical pharmacology of a type I and II, 5-alpha-reductase inhibitor (LY320236) in prostate cancer: elevation of estradiol as possible mechanism of action.
PMID 14751361·Urology·2004
3-trial
Therapeutic considerations for patients with high-risk, nonmetastatic, prostate cancer.
PMID 12198634·Semin Urol Oncol·2002
6-review
Is abiraterone acetate well tolerated and effective in the treatment of castration-resistant prostate cancer?
PMID 18957947·Nat Clin Pract Oncol·2009
8-other
Shared TP53 gene mutation in morphologically and phenotypically distinct concurrent primary small cell neuroendocrine carcinoma and adenocarcinoma of the prostate.
PMID 19125417·Prostate·2009
5-case
Copy number analysis indicates monoclonal origin of lethal metastatic prostate cancer.
PMID 19363497·Nat Med·2009
7-preclinical
LHRH antagonists vs LHRH agonists: which is more beneficial in prostate cancer therapy?
PMID 19626831·Oncology (Williston Park)·2009
8-other
The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.
PMID 18574490·Prostate Cancer Prostatic Dis·2009
8-other
Re: Adaptive therapy for androgen-independent prostate cancer: a randomized selection trial of four regimens.
PMID 18445824·J Natl Cancer Inst·2008
8-other
Does short-term ADT before and during radiation therapy improve outcomes in locally advanced prostate cancer?
PMID 18665153·Nat Clin Pract Urol·2008
8-other
Outcomes of patients after aborted radical cystectomy for intraoperative findings of metastatic disease.
PMID 18727617·BJU Int·2008
8-other
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
PMID 18309951·J Clin Oncol·2008
6-review
Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa.
PMID 18487550·Ann Oncol·2008
3-trial
Phase II trial of docetaxel with rapid androgen cycling for progressive noncastrate prostate cancer.
PMID 18565882·J Clin Oncol·2008
3-trial
Use of percutaneous angioplasty to facilitate implantation of the left ventricular pacemaker lead for CRT.
PMID 18195122·Heart·2008
5-case
Treatment of hormone-refractory prostate cancer with docetaxel or mitoxantrone: relationships between prostate-specific antigen, pain, and quality of life response and survival in the TAX-327 study.
PMID 18451243·Clin Cancer Res·2008
4-observational
Phase I trial of the prostate-specific membrane antigen-directed immunoconjugate MLN2704 in patients with progressive metastatic castration-resistant prostate cancer.
PMID 18362364·J Clin Oncol·2008
3-trial
Antiandrogen withdrawal in castrate-refractory prostate cancer: a Southwest Oncology Group trial (SWOG 9426).
PMID 18383517·Cancer·2008
4-observational
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 600 N WOLFE ST
BALTIMORE, MD 21287 - Phone
- (410) 955-8964
Quick Facts
- NPI
- 1699722850
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile